Project Grant R03HL180982
- The National Institutes of Health National Heart Lung and Blood Institute awarded the Regents of the University of California, San Francisco $168,025 on September 1, 2026, under the Cardiovascular Diseases Research program (CFDA 93.837) to develop and pilot test an intervention for as-needed follow-up care for children with bronchiolitis discharged from emergency departments. The research addresses comparative effectiveness of two common post-discharge follow-up practices: routinely scheduled...
- The National Heart, Lung, and Blood Institute awarded The Regents of the University of California, San Francisco $902,000 on August 1, 2026, under the Cardiovascular Diseases Research program (CFDA 93.837) to develop an abbreviated cardiovascular magnetic resonance imaging solution for time-efficient, cost-effective etiology diagnosis of acute ischemic stroke. The project develops a 10-minute abbreviated cardiovascular MRI protocol designed to identify the underlying cause of acute ischemic...
- The National Heart, Lung, and Blood Institute awarded The Regents of the University of California, San Francisco $200,880 on September 1, 2026, under the Cardiovascular Diseases Research program (CFDA 93.837) to develop integrated host-microbe metagenomic sequencing methods for diagnosing and predicting complications in lung transplant recipients. The project will develop metagenomic classifiers from bronchoalveolar lavage fluid to more accurately diagnose lower respiratory tract infection in...
- The National Heart Lung and Blood Institute awarded the Lundquist Institute for Biomedical Innovation at Harbor-UCLA Medical Center $852,991 on August 15, 2026, under the Cardiovascular Diseases Research program (CFDA 93.837) to conduct a longitudinal study of coronary inflammation detection using computed tomography. The recipient will measure epicardial fat density and peri-coronary fat attenuation in 17,138 non-contrast cardiac CT scans drawn from the Multi-Ethnic Study of Atherosclerosis...
- The National Heart, Lung, and Blood Institute awarded The Regents of the University of California, San Francisco $246,000 on July 6, 2026, under the Cardiovascular Diseases Research program (CFDA 93.837) to calculate in-patient ventricular tachycardia burden and assess its impact on patient outcomes. The research leverages the existing UCSF Ventricular Tachycardia Database, which contains expertly annotated ECG and clinical data from 5,679 consecutively admitted ICU patients with 572,574 hours...
- The National Heart, Lung, and Blood Institute awarded The Regents of the University of California, San Francisco $1,265,021 on September 15, 2025, under the Cardiovascular Diseases Research program (CFDA 93.837). The research investigates pathologic fibroblast subsets unique to silicosis, a chronic and potentially fatal fibrotic disease caused by inhalation of crystalline silica. Recent worldwide outbreaks among workers cutting engineered stone for countertops have underscored the need to...
- The National Heart, Lung, and Blood Institute awarded The Regents of the University of California, San Francisco $163,188 on June 8, 2026, under the Cardiovascular Diseases Research program (CFDA 93.837). The award funds a K08 Mentored Career Development Award to investigate the role of CXCR6+ T-cells in immune checkpoint inhibitor–induced myocarditis. The research characterizes T-cell subtypes within the CXCR6+ population and determines whether CXCR6+ T-cells are necessary and sufficient to...
- The National Heart, Lung, and Blood Institute, part of the Department of Health and Human Services, awarded $795,464 to The Regents of the University of California, San Francisco on July 1, 2026, under the Cardiovascular Diseases Research program (CFDA 93.837). The award funds research into adaptive-like natural killer cells in pulmonary cytomegalovirus reactivation. The project investigates whether local cytomegalovirus-specific natural killer cell immune responses in the lungs potentiate...
- The National Heart, Lung, and Blood Institute awarded The Leland Stanford Junior University $770,000 on April 1, 2026, under the Cardiovascular Diseases Research program (CFDA 93.837) to fund research unraveling endothelial-cardiomyocyte crosstalk in cardiomyopathy using an integrated multimodal approach. The research examines molecular mechanisms by which endothelial dysfunction contributes to cardiac dysfunction in cardiomyopathy, focusing on cell-to-cell signaling between endothelial cells...
- The National Heart, Lung, and Blood Institute awarded The Regents of the University of California, San Francisco $1,559,572 on June 17, 2026, under the Cardiovascular Diseases Research program (CFDA 93.837). The award funds research into the multiciliation cycle, a variant cell cycle mechanism that coordinates centriole biogenesis and ciliogenesis in multiciliated cells lining the mammalian airway. Multiciliated cells defend the lungs from inhaled pathogens and particulates but require...
The National Heart, Lung, and Blood Institute awarded The Regents of the University of California, San Francisco $246,000 on August 14, 2026, under the Cardiovascular Diseases Research program (CFDA 93.837) to analyze clinician-level variation in chest pain admission practices and its impact on downstream patient outcomes. The research will evaluate how emergency department clinicians' admitting tendencies for chest pain patients without acute coronary syndrome evidence affect subsequent testing and clinical outcomes. Using a 20 percent national sample of Medicare claims from 2013 to 2020, the study will profile clinicians' admitting patterns during 2013–2015 and classify them as high or low admitters within each ED. The analysis will then assess ED visits to these clinicians from 2016 to 2020 to determine whether patients seen by high-admitting clinicians undergo more coronary testing and invasive procedures, and whether clinician admitting patterns influence 30- and 180-day outcomes including downstream acute myocardial infarction admissions and all-cause mortality. The project is designed to inform practice feedback interventions to reduce unnecessary hospitalizations and associated costs while maintaining patient safety. Work is performed in San Francisco, California. The period of performance runs from August 14, 2026, through May 31, 2028. The award is classified as a Project Grant.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | $246.0k | 8/17/26 |